Sirlift, 100 mg 28 pcs.

Sertraline is a potent and selective serotonin reuptake inhibitor (5NT). At clinical doses, Sertraline blocks serotonin uptake in human platelets.
Sertraline has no affinity for muscarinic (cholinergic), serotonin, dopamine, histamine, benzodiazepine and adrenergic receptors.

Sertraline does not cause drug dependence, does not have m-cholinoblocking and cardiotoxic effects. It does not increase the activity of the sympathetic nervous system.

In contrast to tricyclic antidepressants it does not increase body weight.

Pharmacokinetics

Sertraline is slowly adsorbed from the gastrointestinal tract. Food intake has no significant effect on the bioavailability of the drug. Sertraline undergoes active first-pass metabolism through the liver. The main metabolite, N-desmethylsertraline, is significantly inferior in activity to sertraline and has almost no antidepressant effect. Equilibrium concentrations are reached after about a week of treatment (once daily), with double cumulation of the drug. Binding to plasma proteins is 98%.

The average half-life of Sertraline is 22-36 hours. Sertraline and N-desmethylsertraline are actively biotransformed; the resulting metabolites are excreted in equal amounts in the feces and urine. Only 0.2% of sertraline is excreted unchanged by the kidneys. Pharmacokinetics of the drug in elderly and young patients is not significantly different.

Sertraline penetrates into the breast milk.

There is no data on its ability to pass through the blood-placental barrier.

Certralin is not dialyzed.

Indications

Active ingredient

Composition

1 coated tablet contains:

the active ingredient:

sertraline hydrochloride 100 mg.

How to take, the dosage

The standard starting dose of Sirlift is 50 mg once daily regardless of meals. The initial effect may appear after 7 days, the full effect of the drug is usually seen after 2-4 weeks of treatment. If there is no effect after several weeks of use, the dose can be gradually increased (by 50 mg per week) to a maximum dose of 200 mg per day at one time.

In long-term use of Sirlift the patient is individually selected the minimum effective maintenance dose.
Does not require dose adjustment in elderly patients and patients with somatic aggravation.

Indications

Initial daily

dosage (mg)

Effective

daily

dosage (mg)

Adults

Depression

50

Obsessive-compulsive disorder

50

75-200

Panic disorder

25

50-200

Post-traumatic stress disorder

25

50-200

Generalized anxiety disorder

50

50-200

Social phobias

50

50-150

Premenstrual syndrome in women

50

50-100

Children 6 – 12 years

Obsessive-compulsive disorder

25

50-100

Adolescents 13-17 years old

Obsessive-compulsive disorder

50

50-150

Interaction

Serious side effects have been described in patients receiving sertraline in combination with MAO inhibitors. Concomitant administration of sertraline with diazepam or tolbutamide may result in changes in serum levels of these drugs.

The concomitant administration of sertraline (200 mg daily) and warfarin may slightly increase prothrombin time. It is necessary to monitor this index at the beginning of treatment with sertraline and after its withdrawal. Cimetidine causes a decrease in clearance of sertraline when they are used together.

Sertraline may inhibit the metabolism of tricyclic antidepressants, so caution should be exercised when using these drugs concomitantly.

Special Instructions

Serlift should not be coadministered with an IMAO or for 14 days after stopping IMAO treatment. After discontinuation of Sirlift, no IMAOs should be prescribed for 14 days. During treatment with Sirlift, caution should be exercised when driving motor vehicles and engaging in potentially hazardous activities that require increased concentration and rapid psychomotor reactions.

Contraindications

Side effects

Nervous system and sensory organs: Drowsiness, dizziness, headache, insomnia, confusion, amnesia, ataxia, dyscoordination, hyper- and paresthesias, hyperkinesias, hypo- and dyskinesias, extrapyramidal disorders, seizures, mydriasis, nystagmus, ptosis, hyporeflexia, aggressiveness, anxiety, psychosis, amnesia, apathy, depersonalization, emotional lability, euphoria, hallucinations, paranoid reactions, somnambulism.

Cardiovascular system and blood (hematopoiesis, hemostasis): arterial hypertension or arterial hypotension, palpitations, chest pain, anemia; rarely – tachycardia, collaptoid states.

Gastrointestinal organs: dry mouth, decreased appetite up to anorexia (rarely – increased appetite, possibly as a consequence of elimination of depression), dyspeptic disorders (flatulence, nausea, vomiting, diarrhea or unstable stools, constipation), Stomach cramps, abdominal pain, pancreatitis, altered liver tests, hepatitis, jaundice or liver failure, dysphagia, irritation of gastrointestinal mucosa, glossitis, gum hypertrophy, ulcerative stomatitis.

Respiratory system: feeling of chest tightness.

Urogenital system disorders: delayed ejaculation, decreased libido, erectile dysfunction, anorgasmia, menstrual cycle disorders, gynecomastia, priapism, dysuria, hyperprolactinemia, galactorrhea.

Allergic reactions: skin redness, urticaria; swelling of the face or lips; skin rash, generalized itching, erythema multiforme.

Others: edema (including periorbital), arthralgia, lymphadenopathy, excessive sweating, weight loss, withdrawal syndrome.

Overdose

Serious symptoms of sertraline overdose have not been found, even when administered in high doses.

Symptoms of overdose: tremor, disorientation, restlessness, muscle hypertonicity, hyperreflexia, myoclonic twitches first in the feet, then spreading throughout the body, abdominal cramps, flatulence, diarrhea, nausea, vomiting, dyspepsia.

The treatment of overdose: there are no specific antidotes. To reduce absorption gastric lavage is possible, the use of activated charcoal. Normal airway patency, oxygenation and ventilation of the lungs should be ensured. The functions of vital organs should be monitored, symptomatic and supportive therapy should be carried out.

Pregnancy use

Adequate controlled trials of sertraline in pregnant and breastfeeding women have not been conducted, Sirlift may be prescribed when the anticipated benefit to the mother exceeds the possible risk to the fetus and child.

Similarities